Detection of Histone H3 Methylation and Acetylation Modifications by Liquid Chromatography-Tandem Mass Spectrometry and Its Application in Epigenetic Drug Evaluation

被引:0
作者
Shi, Qin-Yun [1 ,2 ]
Qu, Min-Min [2 ]
Li, Zhi [2 ]
Ma, Bo [2 ]
Chen, Jia [2 ]
Xu, Bin [2 ]
Xu, Hua [2 ]
Xie, Jian-Wei [2 ]
机构
[1] Qingdao Univ, Sch Pharm, Qingdao 266000, Peoples R China
[2] Natl Key Lab Natl Secur Special Drugs, Beijing 100850, Peoples R China
基金
中国国家自然科学基金;
关键词
Epigenetic drug; Liquid chromatography-tandem mass spectrometry; Histone; Methylation; Acetylation; DRIVER MUTATIONS; H3K27ME3; GENE; CANCER;
D O I
10.19756/j.issn.0253-3820.231468
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
The changes in epigenetic modifications of histones are one of the important factors in cancer development and metastasis, and the development of epigenetic therapies for cancer treatment has led to epigenetic drug screening as a research focus. In this work, the common methylation and acetylation modifications at the N -terminal of cellular histones H3 were quantified by a liquid chromatography -tandem mass spectrometry (LC -MS/ MS) method, and a throughput assay for screening and assessment of epigenetic drug was established. A total of 39 kinds of modification combinations containing common methylation and acetylation sites of H3 peptides were simultaneously monitored by triple quadrupole mass spectrometry in multiple reaction monitoring (MRM) mode. The developed method was applied to analyze HepG2 cells exposed for 24 h to 28 kinds of epigenetic drugs that could modulate the level of methylation or acetylation modifications. Results showed that 25 of these drugs, such as deacetylase inhibitors Abexinostat, Valproic acid and AGK7, induced histone H3 modification changes in the exposed cells that were consistent with those reported in the literature, while other modification changes were also detectable. Three of these drugs, including demethylase inhibitors IOX1, GSK-jl and acetyltransferase inhibitor L002, however, induced modification changes different from those reported in the literature. An overall test match rate of 89.3% was achieved. The established LC-MS/MS method could quantitatively analyze histone H3 modification sites and their changes in cells in a high -throughput and highly sensitive manner, and could be applied to the evaluation of epigenetic drugs with known activities, with good specificity and rich modification information, which was expected to provide a new technological tool for screening and evaluation of epigenetically active compounds and exploration of their mechanism of action.
引用
收藏
页码:818 / 827
页数:10
相关论文
共 38 条
[1]   Regulation of CD4 T-cell differentiation and inflammation by repressive histone methylation [J].
Antignano, Frann ;
Zaph, Colby .
IMMUNOLOGY AND CELL BIOLOGY, 2015, 93 (03) :245-252
[2]   Epigenetic Therapies for Cancer [J].
Bates, Susan E. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (07) :650-663
[3]   Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone [J].
Behjati, Sam ;
Tarpey, Patrick S. ;
Presneau, Nadege ;
Scheipl, Susanne ;
Pillay, Nischalan ;
Van Loo, Peter ;
Wedge, David C. ;
Cooke, Susanna L. ;
Gundem, Gunes ;
Davies, Helen ;
Nik-Zainal, Serena ;
Martin, Sancha ;
McLaren, Stuart ;
Goodie, Victoria ;
Robinson, Ben ;
Butler, Adam ;
Teague, Jon W. ;
Halai, Dina ;
Khatri, Bhavisha ;
Myklebost, Ola ;
Baumhoer, Daniel ;
Jundt, Gernot ;
Hamoudi, Rifat ;
Tirabosco, Roberto ;
Amary, M. Fernanda ;
Futreal, P. Andrew ;
Stratton, Michael R. ;
Campbell, Peter J. ;
Flanagan, Adrienne M. .
NATURE GENETICS, 2013, 45 (12) :1479-U105
[4]   Standardize antibodies used in research [J].
Bradbury, Andrew ;
Plueckthun, Andreas .
NATURE, 2015, 518 (7537) :27-29
[5]   Cognitive epigenetic priming: leveraging histone for amelioration [J].
Burns, Allison M. ;
Graeff, Johannes .
CURRENT OPINION IN NEUROBIOLOGY, 2021, 67 :75-84
[6]   KDM6B is an androgen regulated gene and plays oncogenic roles by demethylating H3K27me3 at cyclin D1 promoter in prostate cancer [J].
Cao, Zhi ;
Shi, Xiaolei ;
Tian, Feng ;
Fang, Yu ;
Wu, Jason Boyang ;
Mrdenovic, Stefan ;
Nian, Xinwen ;
Ji, Jin ;
Xu, Huan ;
Kong, Chen ;
Xu, Yalong ;
Chen, Xi ;
Huang, Yuhua ;
Wei, Xuedong ;
Yu, Yongwei ;
Yang, Bo ;
Chung, Leland W. K. ;
Wang, Fubo .
CELL DEATH & DISEASE, 2021, 12 (01)
[7]   Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1 [J].
Dai, Xing-Jie ;
Liu, Ying ;
Xue, Lei-Peng ;
Xiong, Xiao-Peng ;
Zhou, Ying ;
Zheng, Yi-Chao ;
Liu, Hong-Min .
JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (05) :2466-2488
[8]  
[丁勇 Ding Yong], 2017, [中国科学. 生命科学, Scientia Sinica Vitae], V47, P3
[9]   Histone-writer cancer drugs enter center stage [J].
Garber, Ken .
NATURE BIOTECHNOLOGY, 2020, 38 (08) :909-912
[10]   Chemical derivatization of histones for facilitated analysis by mass spectrometry [J].
Garcia, Benjamin A. ;
Mollah, Sahana ;
Ueberheide, Beatrix M. ;
Busby, Scott A. ;
Muratore, Tara L. ;
Shabanowitz, Jeffrey ;
Hunt, Donald F. .
NATURE PROTOCOLS, 2007, 2 (04) :933-938